INDEMNIFICATION AGREEMENTIndemnification Agreement • June 21st, 2019 • Fulcrum Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of [ ], 20[ ] by and between Fulcrum Therapeutics, Inc., a Delaware corporation (the “Company”), and [ ] (“Indemnitee”) [[Solely with respect to officers and directors that execute this form of indemnification agreement on or prior to the Company’s initial public offering:] and shall be effective as of the effectiveness of a Registration Statement on Form S-1 relating to the initial registration under the Securities Act of 1933, as amended, of shares of the Company’s common stock].
FULCRUM THERAPEUTICS, INC. COMMON STOCK, PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • June 21st, 2019 • Fulcrum Therapeutics, Inc. • Pharmaceutical preparations • New York
FULCRUM THERAPEUTICS INCENTIVE STOCK OPTION AGREEMENT GRANTED UNDER 2016 STOCK INCENTIVE PLANIncentive Stock Option Agreement • June 21st, 2019 • Fulcrum Therapeutics, Inc. • Pharmaceutical preparations
FULCRUM THERAPEUTICS, INC. NONSTATUTORY STOCK OPTION AGREEMENT GRANTED UNDER 2016 STOCK INCENTIVE PLANNonstatutory Stock Option Agreement • June 21st, 2019 • Fulcrum Therapeutics, Inc. • Pharmaceutical preparations
RIGHT OF REFERENCE AND LICENSE AGREEMENTRight of Reference and License Agreement • June 21st, 2019 • Fulcrum Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS RIGHT OF REFERENCE AND LICENSE AGREEMENT (this “Agreement”), dated as of February 8, 2019 (the “Effective Date”), is made and entered into by and between GlaxoSmithKline Intellectual Property (No. 2) Limited, a company organized under the laws of England and Wales and having a place of business at 980 Great West Road, Brentford, Middlesex TW8 9GS England (“GIP2”), GlaxoSmithKline LLC, a Delaware limited liability company having a place of business at 1250 S. Collegeville Road, Collegeville, PA 19426-0989 (“GSK LLC”) and Glaxo Group Limited, a company organized under the laws of England and Wales and having a place of business at 980 Great West Road, Brentford, Middlesex TW8 9GS England (“GGL”) (GIP2, GSK LLC and GGL are collectively referred to herein as “GSK”), and Fulcrum Therapeutics, Inc., a Delaware corporation having a place of business at 26 Landsdowne Street, Cambridge, MA 02139 (“Fulcrum”). GSK and Fulcrum may be referred to herein individually as a “Party” and collective
LEASE FOR Cambridge, MassachusettsBasic Lease Terms • June 21st, 2019 • Fulcrum Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
FULCRUM THERAPEUTICS, INC. RESTRICTED STOCK AGREEMENT GRANTED UNDER 2016 STOCK INCENTIVE PLANRestricted Stock Agreement • June 21st, 2019 • Fulcrum Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Restricted Stock Agreement (the “Agreement”) is made this [ ] day of [ ], 2016, between Fulcrum Therapeutics, Inc., a Delaware corporation (the “Company”), and [ ] (the “Participant”).
FULCRUM THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT August 24, 2018Adoption Agreement • June 21st, 2019 • Fulcrum Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of August 24, 2018, by and among Fulcrum Therapeutics, Inc., a Delaware corporation (the “Company”), and each investor listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor.”
